198 related articles for article (PubMed ID: 36928998)
21. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).
Golding B; Luu A; Jones R; Viloria-Petit AM
Mol Cancer; 2018 Feb; 17(1):52. PubMed ID: 29455675
[TBL] [Abstract][Full Text] [Related]
22. Integrative nomogram of CT imaging, clinical, and hematological features for survival prediction of patients with locally advanced non-small cell lung cancer.
Wang L; Dong T; Xin B; Xu C; Guo M; Zhang H; Feng D; Wang X; Yu J
Eur Radiol; 2019 Jun; 29(6):2958-2967. PubMed ID: 30643940
[TBL] [Abstract][Full Text] [Related]
23. Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
Ito K; Hataji O; Kobayashi H; Fujiwara A; Yoshida M; D'Alessandro-Gabazza CN; Itani H; Tanigawa M; Ikeda T; Fujiwara K; Fujimoto H; Kobayashi T; Gabazza EC; Taguchi O; Yamamoto N
J Thorac Oncol; 2017 Feb; 12(2):390-396. PubMed ID: 27498387
[TBL] [Abstract][Full Text] [Related]
24. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
[TBL] [Abstract][Full Text] [Related]
25. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
[TBL] [Abstract][Full Text] [Related]
26. Homology-based radiomic features for prediction of the prognosis of lung cancer based on CT-based radiomics.
Kadoya N; Tanaka S; Kajikawa T; Tanabe S; Abe K; Nakajima Y; Yamamoto T; Takahashi N; Takeda K; Dobashi S; Takeda K; Nakane K; Jingu K
Med Phys; 2020 Jun; 47(5):2197-2205. PubMed ID: 32096876
[TBL] [Abstract][Full Text] [Related]
27. Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer.
Jahanzeb M; Lin HM; Pan X; Yin Y; Wu Y; Nordstrom B; Socinski MA
Oncologist; 2020 Oct; 25(10):867-877. PubMed ID: 32490560
[TBL] [Abstract][Full Text] [Related]
28. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
29. Development of a radiomics nomogram based on the 2D and 3D CT features to predict the survival of non-small cell lung cancer patients.
Yang L; Yang J; Zhou X; Huang L; Zhao W; Wang T; Zhuang J; Tian J
Eur Radiol; 2019 May; 29(5):2196-2206. PubMed ID: 30523451
[TBL] [Abstract][Full Text] [Related]
30. The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer.
Heo JY; Park C; Keam B; Ock CY; Kim M; Kim TM; Kim DW; Kim SH; Kim YJ; Lee JS; Heo DS
Thorac Cancer; 2019 Nov; 10(11):2117-2123. PubMed ID: 31509890
[TBL] [Abstract][Full Text] [Related]
31. Application and limitation of radiomics approach to prognostic prediction for lung stereotactic body radiotherapy using breath-hold CT images with random survival forest: A multi-institutional study.
Kakino R; Nakamura M; Mitsuyoshi T; Shintani T; Kokubo M; Negoro Y; Fushiki M; Ogura M; Itasaka S; Yamauchi C; Otsu S; Sakamoto T; Sakamoto M; Araki N; Hirashima H; Adachi T; Matsuo Y; Mizowaki T
Med Phys; 2020 Sep; 47(9):4634-4643. PubMed ID: 32645224
[TBL] [Abstract][Full Text] [Related]
32. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.
Ma HC; Liu YH; Ding KL; Liu YF; Zhao WJ; Zhu YJ; Chang XS; Chen YD; Xiao ZZ; Yu YY; Zhou R; Zhang HB
BMC Cancer; 2021 Nov; 21(1):1278. PubMed ID: 34836510
[TBL] [Abstract][Full Text] [Related]
33. Alectinib: A Review in Advanced, ALK-Positive NSCLC.
Paik J; Dhillon S
Drugs; 2018 Aug; 78(12):1247-1257. PubMed ID: 30030733
[TBL] [Abstract][Full Text] [Related]
34. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
Mok T; Camidge DR; Gadgeel SM; Rosell R; Dziadziuszko R; Kim DW; Pérol M; Ou SI; Ahn JS; Shaw AT; Bordogna W; Smoljanović V; Hilton M; Ruf T; Noé J; Peters S
Ann Oncol; 2020 Aug; 31(8):1056-1064. PubMed ID: 32418886
[TBL] [Abstract][Full Text] [Related]
35. Real-world adherence and persistence with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer.
Ganti AK; Lin CW; Yang E; Wong WB; Ogale S
J Manag Care Spec Pharm; 2022 Mar; 28(3):305-314. PubMed ID: 34913728
[No Abstract] [Full Text] [Related]
36. A radiomics-based deep learning approach to predict progression free-survival after tyrosine kinase inhibitor therapy in non-small cell lung cancer.
Lu CF; Liao CY; Chao HS; Chiu HY; Wang TW; Lee Y; Chen JR; Shiao TH; Chen YM; Wu YT
Cancer Imaging; 2023 Jan; 23(1):9. PubMed ID: 36670497
[TBL] [Abstract][Full Text] [Related]
37. Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib.
Hida T; Dahlberg SE; Lydon CA; Hatabu H; Johnson BE; Awad MM; Nishino M
J Thorac Imaging; 2020 Mar; 35(2):101-107. PubMed ID: 30985604
[TBL] [Abstract][Full Text] [Related]
38. Enhancing brain metastasis prediction in non-small cell lung cancer: a deep learning-based segmentation and CT radiomics-based ensemble learning model.
Gong J; Wang T; Wang Z; Chu X; Hu T; Li M; Peng W; Feng F; Tong T; Gu Y
Cancer Imaging; 2024 Jan; 24(1):1. PubMed ID: 38167564
[TBL] [Abstract][Full Text] [Related]
39. An [
Meng N; Feng P; Yu X; Wu Y; Fu F; Li Z; Luo Y; Tan H; Yuan J; Yang Y; Wang Z; Wang M
Eur Radiol; 2024 Jan; 34(1):318-329. PubMed ID: 37530809
[TBL] [Abstract][Full Text] [Related]
40. Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.
Naik J; Beavers N; Nilsson FOL; Iadeluca L; Lowry C
Appl Health Econ Health Policy; 2023 Jul; 21(4):661-672. PubMed ID: 37173513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
